drugset / Trial / NCT05511831

The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI

NCT05511831

Phase 4 Unknown 60 enrolled Peking University Third Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of ketotifen (MC stabilizer) on the basis of standard treatment after primary PCI in STEMI patients. The ketotifen group and the control group were the ketotifen group and the control group. The control group continued to receive STEMI standard treatment. The ketotifen group received ketotifen for 3 months on the basis of standard treatment within 24 hours after primary PCI, and was followed up for 1 year. Infarct size, as well as differences in echocardiography, markers of two-dimensional speckle tracking, inflammatory factors and MC markers, and major adverse cardiovascular events.

Timeline

Start
2022-09-01
Primary completion
2023-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketotifen Small molecule 1 mg